Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed Sage’s valuation following Biogen’s (BIIB) takeout proposal and raised its price target, but sees a “largely balanced risk/reward” and remains Neutral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Rejects Biogen Bid but Could be Open to Other Offers
- M&A News: Sage Rejects Biogen’s $469M Takeover Bid over Valuation Concerns
- China’s DeepSeek sinks tech, AT&T reports Q4 beat: Morning Buzz
- Sage Therapeutics initiates strategic review, rejects Biogen proposal
- Biotech Alert: Searches spiking for these stocks today